Does omission of a loose seton before sphincter-preserving surgery achieve non-inferior fistula closure compared with routine loose seton placement in adults with single-tract cryptoglandular anal fistula in the Netherlands? Study protocol for the SETON multicentre randomised controlled non-inferiority trial and cost-utility analysis
- 1Department of Surgery, Amsterdam UMC, Amsterdam, The Netherlands
- 2Department of Surgery, Proctos Kliniek, Bilthoven, The Netherlands
Abstract
Introduction: Cryptoglandular anal fistulas are burdensome, often recurrent and frequently treated in two stages using a loose seton before definitive sphincter-preserving surgery. Although this practice is common, high-quality evidence supporting improved healing or functional outcomes is lacking. A trial is needed to determine whether omitting routine seton placement can reduce procedures, patient burden and costs without compromising fistula closure.
Methods and analysis: The SETON trial is a multicentre, randomised, unblinded non-inferiority trial with an integrated cost-utility analysis. Adults with a single-tract non-purulent mid-high or high cryptoglandular anal fistula will be randomised to loose seton placement for 8 weeks followed by definitive sphincter-preserving surgery, or to direct sphincter-preserving surgery without prior seton placement. The primary endpoint is fistula closure 26 weeks after final surgery, defined clinically and if needed confirmed by MRI or endoanal ultrasound. Secondary outcomes include recurrence, postoperative complications, pain, re-interventions, continence, fistula-related quality of life, generic health-related quality of life, return to work and cost-effectiveness. A sample size has been calculated for a non-inferiority design with fistula closure at 26 weeks as the primary endpoint. Assuming a conservative closure rate of 60% in the standard-care seton group, a one-sided alpha of 0.05, 80% power and a non-inferiority margin of 15 percentage points, 126 patients are required per group for analysis. Allowing for approximately 10% loss to follow-up, the total sample size will be 277 patients. Data will be analysed according to the intention-to-treat and per-protocol principle.
Ethics and dissemination: The protocol has been approved by the Medical Ethics Review Committee of the Amsterdam University Medical Center, location AMC (reference number: 2025.0826—NL-010338 R031541). Findings will be disseminated in peer-reviewed journals and presented at conferences, whether they are positive, negative or inconclusive.
Trial registration number: NL-010338
Related
- Evaluation of percutaneous cryoneurotomy compared with surgical open neurotomy for the management of post-stroke spastic equinovarus foot in France: protocol for a multicentre, randomised controlled, open-label, non-inferiority trial
- Lesion sterilisation and tissue repair with chloramphenicol, tetracycline, zinc oxide-eugenol paste compared to zinc oxide-eugenol pulpectomy in primary molars: Two-year follow-up findings of a multicentre non-inferiority randomised clinical trial
- Topical trichloroacetic acid versus electrocautery for treatment of anal intraepithelial neoplasia in people living with HIV: a multicentre, randomised, non-inferiority trial (TECAIN-study)
- Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
- Discontinuation of statins for primary prevention of atherosclerotic cardiovascular disease in adults aged 75 years or older (SAGA/SITE): a multicentre, open-label, pragmatic, non-inferiority randomised trial
BibTeX
@article{elwakel2026does,
title = {{Does omission of a loose seton before sphincter-preserving surgery achieve non-inferior fistula closure compared with routine loose seton placement in adults with single-tract cryptoglandular anal fistula in the Netherlands? Study protocol for the SETON multicentre randomised controlled non-inferiority trial and cost-utility analysis}},
author = {Ahmed A Elwakel and Pieter Van Hagen and Ruben Veldkamp and Susan van Dieren and Willem A Bemelman and Ingrid J M Han-Geurts},
journal = {BMJ Open},
year = {2026},
month = oct,
doi = {10.1136/bmjopen-2026-122832},
url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-122832},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Does omission of a loose seton before sphincter-preserving surgery achieve non-inferior fistula closure compared with routine loose seton placement in adults with single-tract cryptoglandular anal fistula in the Netherlands? Study protocol for the SETON multicentre randomised controlled non-inferiority trial and cost-utility analysis
AU - Ahmed A Elwakel
AU - Pieter Van Hagen
AU - Ruben Veldkamp
AU - Susan van Dieren
AU - Willem A Bemelman
AU - Ingrid J M Han-Geurts
PY - 2026
DA - 2026/10/06
JO - BMJ Open
DO - 10.1136/bmjopen-2026-122832
UR - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-122832
AB - Introduction: Cryptoglandular anal fistulas are burdensome, often recurrent and frequently treated in two stages using a loose seton before definitive sphincter-preserving surgery. Although this practice is common, high-quality evidence supporting improved healing or functional outcomes is lacking. A trial is needed to determine whether omitting routine seton placement can reduce procedures, patient burden and costs without compromising fistula closure. Methods and analysis: The SETON trial is a multicentre, randomised, unblinded non-inferiority trial with an integrated cost-utility analysis. Adults with a single-tract non-purulent mid-high or high cryptoglandular anal fistula will be randomised to loose seton placement for 8 weeks followed by definitive sphincter-preserving surgery, or to direct sphincter-preserving surgery without prior seton placement. The primary endpoint is fistula closure 26 weeks after final surgery, defined clinically and if needed confirmed by MRI or endoanal ultrasound. Secondary outcomes include recurrence, postoperative complications, pain, re-interventions, continence, fistula-related quality of life, generic health-related quality of life, return to work and cost-effectiveness. A sample size has been calculated for a non-inferiority design with fistula closure at 26 weeks as the primary endpoint. Assuming a conservative closure rate of 60% in the standard-care seton group, a one-sided alpha of 0.05, 80% power and a non-inferiority margin of 15 percentage points, 126 patients are required per group for analysis. Allowing for approximately 10% loss to follow-up, the total sample size will be 277 patients. Data will be analysed according to the intention-to-treat and per-protocol principle. Ethics and dissemination: The protocol has been approved by the Medical Ethics Review Committee of the Amsterdam University Medical Center, location AMC (reference number: 2025.0826—NL-010338 R031541). Findings will be disseminated in peer-reviewed journals and presented at conferences, whether they are positive, negative or inconclusive. Trial registration number: NL-010338
SN - 2044-6055
SN - 2044-6055
ER -